Mauritius

Private French biotech company Abivax is planning an IPO on the Paris Euronext market to raise funds for the clinical development programs for its two lead compounds, ABX203 and ABX464, for hepatitis B and HIV respectively.

Biocon has reported a 15% increase in revenues to INR8.54bn ($134.8m) for the fourth quarter ended March 2015, backed by the strong showing of its IPO-bound research services subsidiary, Syngene, and a 12% growth in its biopharma business.

IPO-bound Syngene, the research services arm of India's Biocon, expects to evolve into a contract research and manufacturing services (CRAMS) organisation with commercial-scale manufacturing capabilities.

Private equity player Carlyle has exited India's Claris Lifesciences, ending a nine-year association with the Ahmedabad-based injectables company.

Singapore government investment arm Temasek is pumping in about INR9.45bn ($151.6m) for about 3.8% in Glenmark Pharmaceuticals – funds that the Indian firm expects to use to retire debt.

Biocon has outlined definitive plans to take public its research services arm, Syngene, and expects to offload 10-15% from its majority stake via an offer for sale.

Niche active pharmaceutical ingredient (API) players in India continue to attract private equity interest - the latest deal involving Warburg Pincus' acquisition of a minority stake in Laurus Labs for about INR5.50bn ($92m).

Just over a week after GE Capital's exit from Biocon's research services arm, Syngene International, Mauritius-based investment vehicle Silver Leaf Oak has picked up 10% in Syngene for INR3.8bn ($62.4m).

GE Capital has divested its 7.69% holding in Biocon's research services arm, Syngene International – a unit which the Indian biopharmaceutical company hopes to take public.

The institutional investor, Stream Value Fund, is to back the founders of Transgene Biotek as the Indian firm seeks to delist itself from the Bombay Stock Exchange.